Lipid nanoparticles (LNPs) have played a critical role as a therapeutic delivery vehicle on a global stage due to the COVID-19 pandemic. Their development along with their cargo, mRNA, require specific modifications for successful delivery and efficacy. As with any therapy, analytical characterization including identity, purity and degradation products need to be established and set as a baseline for each lipid constituent and the entire four lipid complex. Due to the high demand of LNP many in this field are sourcing their raw materials from multiple vendors thus creating a greater need for an analytical fingerprint to identify similarities or differences. Because lipids are spectroscopically silent many analytical tools simply don’t apply. However, mass spectrometry paired with liquid chromatography is absolutely applicable. LC enables separation of the lipids in a complex mixture and the addition of MS provides further confidence in identification, especially identification and monitoring of possible low-level degradants that can foul the therapy. For this study of complex mixtures and single component analysis, the BioAccord System, an ACQUITY UPLC I-Class LC coupled with ACQUITY RDa Detector was used. The BioAccord was able to identify low levels of each LNP component and provide a fingerprint for each component in the complex mixture for confident identity and impurity detection that will enable consistent final products regardless of the original source.